Ryvu Therapeutics S.A. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was PLN 0.26261 million compared to PLN 0.309557 million a year ago. Revenue was PLN 7.54 million compared to PLN 5.51 million a year ago. Net loss was PLN 36.92 million compared to PLN 24.24 million a year ago. Basic loss per share from continuing operations was PLN 2.011 compared to PLN 1.321 a year ago. Diluted loss per share from continuing operations was PLN 2.011 compared to PLN 1.321 a year ago.
For the six months, sales was PLN 0.490799 million compared to PLN 0.741363 million a year ago. Revenue was PLN 14.52 million compared to PLN 12.06 million a year ago. Net loss was PLN 63.46 million compared to PLN 37.81 million a year ago. Basic loss per share from continuing operations was PLN 3.457 compared to PLN 2.06 a year ago. Diluted loss per share from continuing operations was PLN 3.457 compared to PLN 2.06 a year ago.